A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancer
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Merck Sharp & Dohme LLC
- Enrolment target
- 220
- Started
- 20 June 2024
- Main results due
- 16 October 2029
- Study sites
- 55
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer * Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer * Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer * Advanced and/or unresectable BTC and has not received prior therapy for the cancer * For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of severe eye disease * For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention * History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
What this study is about
In the sponsor’s own words, from the registry.
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:
* About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Study sites(55)
UCLA ( Site 0317)
Los Angeles, California, United States
Recruiting
University of Colorado Anschutz Medical Campus ( Site 0299)
Aurora, Colorado, United States
Recruiting
University of Colorado Anschutz Medical Campus ( Site 0325)
Aurora, Colorado, United States
Recruiting
University of Colorado Anschutz Medical Campus ( Site 0326)
Aurora, Colorado, United States
Recruiting
Sibley Memorial Hospital ( Site 0310)
Washington D.C., District of Columbia, United States
Recruiting
University of Florida College of Medicine ( Site 0281)
Gainesville, Florida, United States
Recruiting
Mount Sinai Cancer Center ( Site 0287)
Miami Beach, Florida, United States
Recruiting
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303)
Marietta, Georgia, United States
Completed
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327)
Mineola, New York, United States
Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324)
New York, New York, United States
Recruiting
University of Texas MD Anderson Cancer Center ( Site 0316)
Houston, Texas, United States
Recruiting
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295)
Roanoke, Virginia, United States
Recruiting
University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293)
Madison, Wisconsin, United States
Recruiting
Westmead Hospital ( Site 0003)
Westmead, New South Wales, Australia
Recruiting
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 0001)
Brisbane, Queensland, Australia
Recruiting
Epworth Freemasons ( Site 0005)
East Melbourne, Victoria, Australia
Recruiting
Frankston Hospital-Oncology and Haematology ( Site 0004)
Frankston, Victoria, Australia
Recruiting
One Clinical Research ( Site 0002)
Nedlands, Western Australia, Australia
Recruiting
The Ottawa Hospital Cancer Centre ( Site 0027)
Ottawa, Ontario, Canada
Recruiting
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Montreal, Quebec, Canada
Recruiting
McGill University Health Centre ( Site 0023)
Montreal, Quebec, Canada
Active, not recruiting
James Lind Centro de Investigacion del Cancer ( Site 0048)
Temuco, Araucania, Chile
Recruiting
FALP-UIDO ( Site 0041)
Providencia, Region M. de Santiago, Chile
Recruiting
Clínica UC San Carlos de Apoquindo ( Site 0043)
Santiago, Region M. de Santiago, Chile
Recruiting
Bradfordhill-Clinical Area ( Site 0047)
Santiago, Region M. de Santiago, Chile
Recruiting
Beijing Cancer hospital-Digestive Oncology ( Site 0061)
Beijing, Beijing Municipality, China
Recruiting
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 0063)
Fuzhou, Fujian, China
Recruiting
Wuhan Union Hospital Cancer Center. ( Site 0064)
Wuhan, Hubei, China
Active, not recruiting
Hunan Cancer Hospital-intervention department ( Site 0066)
Changsha, Hunan, China
Active, not recruiting
Renji Hospital Shanghai Jiao Tong University School of Medicine-Oncology Department ( Site 0067)
Shanghai, Shanghai Municipality, China
Active, not recruiting
West China Hospital, Sichuan University ( Site 0068)
Chengdu, Sichuan, China
Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0101)
Milan, Lombardy, Italy
Recruiting
ASST Grande Ospedale Metropolitano Niguarda ( Site 0102)
Milan, Lombardy, Italy
Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0103)
Roma, Italy
Recruiting
National Cancer Center Hospital East ( Site 0121)
Kashiwa, Chiba, Japan
Recruiting
Kanagawa Cancer Center ( Site 0122)
Yokohama, Kanagawa, Japan
Recruiting
Seoul National University Hospital ( Site 0161)
Seoul, South Korea
Recruiting
Severance Hospital, Yonsei University Health System ( Site 0164)
Seoul, South Korea
Recruiting
Asan Medical Center ( Site 0163)
Seoul, South Korea
Recruiting
Samsung Medical Center ( Site 0162)
Seoul, South Korea
Recruiting
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 0183)
Madrid, Madrid, Comunidad de, Spain
Recruiting
Hospital Universitario Central de Asturias-Medical Oncology ( Site 0182)
Oviedo, Principality of Asturias, Spain
Active, not recruiting
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0181)
Barcelona, Spain
Recruiting
Hôpitaux Universitaires de Genève (HUG) ( Site 0202)
Geneva, Canton of Geneva, Switzerland
Recruiting
Ospedale Regionale Bellinzona e Valli ( Site 0201)
Bellinzona, Canton Ticino, Switzerland
Recruiting
China Medical University Hospital ( Site 0223)
Taichung, Taiwan
Recruiting
National Cheng Kung University Hospital-Clinical Trial Center ( Site 0224)
Tainan, Taiwan
Recruiting
National Taiwan University Hospital-Oncology ( Site 0225)
Taipei, Taiwan
Recruiting
Taipei Veterans General Hospital ( Site 0221)
Taipei, Taiwan
Recruiting
Chang Gung Medical Foundation-Linkou Branch ( Site 0222)
Taoyuan, Taiwan
Recruiting
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0241)
Ankara, Turkey (Türkiye)
Completed
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 0242)
Ankara, Turkey (Türkiye)
Completed
Barts Health NHS Trust ( Site 0263)
London, England, United Kingdom
Recruiting
Royal Free Hospital ( Site 0262)
London, England, United Kingdom
Recruiting
University Hospital Coventry & Warwickshire ( Site 0266)
Coventry, United Kingdom
Recruiting
Showing 55 of 55 sites. 47 of the 55 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06428409. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me